AdvisorNet Financial Inc trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,486 shares of the company’s stock after selling 4,044 shares during the quarter. AdvisorNet Financial Inc’s holdings in Johnson & Johnson were worth $6,819,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Sector Gamma AS increased its position in Johnson & Johnson by 0.3% during the first quarter. Sector Gamma AS now owns 117,532 shares of the company’s stock worth $15,412,000 after buying an additional 303 shares during the last quarter. Tradewinds Capital Management LLC increased its position in Johnson & Johnson by 1.3% during the first quarter. Tradewinds Capital Management LLC now owns 7,602 shares of the company’s stock worth $997,000 after buying an additional 101 shares during the last quarter. Dempze Nancy E increased its position in Johnson & Johnson by 0.4% during the second quarter. Dempze Nancy E now owns 20,907 shares of the company’s stock worth $2,939,000 after buying an additional 80 shares during the last quarter. Bessemer Group Inc. increased its position in Johnson & Johnson by 10.3% during the second quarter. Bessemer Group Inc. now owns 268,577 shares of the company’s stock worth $37,769,000 after buying an additional 25,097 shares during the last quarter. Finally, Private Asset Management Inc. grew its position in shares of Johnson & Johnson by 0.5% in the second quarter. Private Asset Management Inc. now owns 93,956 shares of the company’s stock valued at $13,213,000 after purchasing an additional 425 shares during the last quarter. 67.44% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by company insiders.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Thursday, July 16th. The company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. The firm had revenue of $18.34 billion during the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.58 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 7.85 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date was Monday, August 24th. Johnson & Johnson’s dividend payout ratio is 46.54%.
Several equities research analysts have recently issued reports on JNJ shares. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target on the stock. in a research report on Tuesday, July 7th. Raymond James raised their price target on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. SVB Leerink reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Friday, September 4th. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $163.00.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Most Volatile Stocks – What Investors Need to Know to Maximize ROI
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.